The polyphenols (-)-Epigallocatechin-3-gallate and luteolin synergistically inhibit TGF-β-induced myofibroblast phenotypes through rhoa and ERK inhibition

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Gray, Alana L ^a   Stephens, Charles A ^a   Bigelow, Rebecca L H ^a   Coleman, David T ^a   Cardelli, James A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; FIBRONECTIN; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CATECHIN;

ADULT; ARTICLE; CANCER GROWTH; CELL INVASION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MYOFIBROBLAST; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; METABOLISM;

CATECHIN; CELL LINE; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUTEOLIN; MYOFIBROBLASTS; PHENOTYPE; RHOA GTP-BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907482654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109208     Document Type: Article

References (59)

1. National Cancer Institute Website. SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute. Bethesda, MD, Available: http://seer.cancer.gov/statfacts/html/prost.html. Accessed 2014 Sep 10.
2. Jain RK (2013). Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31: 2205-18.
3. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, et al. (2005). PAR1 Is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-13.
4. Kalluri R, Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
5. Polanska UM, Orimo A (2013). Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol. 228: 1651-57.
6. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, et al. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 70: 6945-56.
7. Ronnov-Jessen L, Petersen OW, Bissell MJ (1996). Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69-125.
8. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-48.
9. Chen JL-Y, Espinosa I, Lin AY, Liao OY-W, van de Rijn M, et al. (2013). Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res 19: 5127-35.
10. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, et al. (2003). Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9: 4792-801.
11. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, et al. (2012). Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 109: 15101-08.
12. Surh YJ (2003). Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780.
13. Gutierrez-Venegas G, Alonso LO, Ventura-Arroyo JA, Hernandez-Bermudez C (2013). Myricetin suppresses lipoteichoic acid-induced interleukin-1b and cyclooxygenase-2 expression in human gingival fibroblasts. Microbiol Immunol 57: 849-56.
14. Nazaruk J, Galicka A (2014) The influence of selected flavonoids from the leaves of Cirsium palustre (L.) Scop. on collagen expression in human skin fibroblasts. Phytother Res doi: 10.1002/ptr.5143.
15. Stipcevic T, Piljac J, Vanden Berghe D (2006). Effect of different flavonoids on collagen synthesis in human fibroblasts. Plant Foods Hum Nutr 61: 29-34.
16. Chen YH, Liang CM, Chen CL, Chen JT, Chang YH, et al. (2013). Silibinin inhibits myofibroblast transdifferentiation in human tenon fibroblasts and reduces fibrosis in a rabbit trabeculectomy model. Acta Ophthalmol 91: e506-15.
17. Wojcik KA, Skoda M, Koczukiewicz P, Sanak M, Czyz J, et al. (2013). Apigenin inhibits TGF-b1 induced fibroblast-to-myofibroblast transition in human lung fibroblast populations. Pharmacol Rep 65: 164-72.
18. Relat J, Blancafort A, Oliveras G, Cufi S, Haro D, et al. (2012). Different fatty acid metabolism effects of (-)-Epigallocatechin-3-Gallate and C75 in adeno-carcinoma lung cancer. BMC Cancer 12: 280.
19. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, et al. (2011). Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 25: 1198-207.
20. Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, et al. (2009). The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 15: 4885-94.
21. Lamy S, Bédard V, Labbé D, Sartelet H, Barthomeuf C, et al. (2008). The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through Inhibition of PDGFR-b phosphorylation. Cancer Prev Res 1: 452-59.
22. Coleman DT, Bigelow R, Cardelli JA (2009). Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 8: 214-24.
23. Majumdar D, Jung K-H, Zhang H, Nannapaneni S, Wang X, et al. (2014). Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev Res 7: 65-73.
24. Bigelow RLH, Cardelli JA (2006). The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 25: 1922-30.
25. Sah JF, Balasubramanian S, Eckert RL, Rorke EA (2004). Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway: evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 279: 12755-62.
26. Duhon D, Bigelow RLH, Coleman DT, Steffan JJ, Yu C, et al. (2010). The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog 49: 739-49.
27. McLarty J, Bigelow RLH, Smith M, Elmajian D, Ankem M, et al. (2009). Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res 2: 673-82.
28. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR (2008). Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72: 205-13.
29. Dakhova O, Rowley D, Ittmann M (2014). Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res 20: 100-109.
30. Chou T-CaM N (2007) CompuSyn software for drug combinations and for general dose effect analysis, and user's guide. ComboSyn, Inc Paramus, NJ. [www.combosyn.com].
31. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, et al. (2013). Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15: 637-46.
32. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, et al. (1999). A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20: 1185-92.
33. Ronnov-Jessen L, Peterson OW (1993). Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68: 696-707.
34. Chuu C-P, Chen R-Y, Kokontis JM, Hiipakka RA, Liao S (2009). Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 275: 86-92.
35. Johnson JL, Gonzalez de Mejia E (2013). Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. Food Chem Toxicol 60: 83-91.
36. Shi Y, Massague J (2003). Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 113: 685-700.
37. Ding Q, Gladson CL, Wu H, Hayasaka H, Olman MA (2008). Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem 283: 26839-49.
38. Yumei F, Zhou Y, Zheng S, Chen A (2006). The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab Invest 86: 697-709.
39. Lo RS, Massague J (1999). Ubiquitin-dependent degradation of TGF-β-activated Smad2. Nat Cell Biol 1: 472-78.
40. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, et al. (2010). Autocrine TGF-b and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107: 20009-14.
41. Thomas PE, Peters-Golden M, White ES, Thannickal VJ, Moore BB (2007). PGE2 inhibition of TGF-β-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol - Lung Cell Mol Physiol 293: L417-L428.
42. Chen C-L, Huang SS, Huang JS (2008). Cholesterol modulates cellular TGF-b responsiveness by altering TGF-b binding to TGF-b receptors. J Cell Physiol 215: 223-33.
43. Finger EC, Lee NY, You H-j, Blobe GC (2008). Endocytosis of the type III transforming growth factor-b (TGF-b) receptor through the clathrin-independent/lipid raft pathway regulates TGF-b signaling and receptor down-regulation. J Biol Chem 283: 34808-18.
44. Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, et al. (2007). The inhibitory effect of (-)-Epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 67: 6493-501.
45. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV (2005). Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 280: 5636-45.
46. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, et al. (2008). RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 57: 1683-92.
47. Cali G, Mazzarella C, Chiacchio M, Negri R, Retta SF, et al. (1999) RhoA activity is required for fibronectin assembly and counteracts beta1B integrin inhibitory effect in FRT epithelial cells. J Cell Sci 112; 957-65.
48. Wheeler AP, Ridley AJ (2004). Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res Cytoskeleton Special Review Issue 301: 43-49.
49. Porter KE, Turner NA, O'Regan DJ, Balmforth AJ, Ball SG (2004). Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 61: 745-55.
50. Kang JS, Park I-H, Cho J-S, Hong S-M, Kim TH, et al. (2014). Epigallocatechin-3-Gallate inhibits collagen production of nasal polyp-derived fibroblasts. Phytother Res 28: 98-103.
51. Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, et al. (2010). Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology 49: 2024-36.
52. Tse JM, Cheng G, Tyrrell JA, Wilcox-Adelman SA, Boucher Y, et al. (2012). Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci U S A 109: 911-16.
53. Peng F, Wu D, Ingram AJ, Zhang B, Gao B, et al. (2007). RhoA activation in mesangial cells by mechanical strain depends on caveolae and caveolin-1 interaction. J Am Soc Neph 18: 189-98.
54. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, et al. (2002). Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923.
55. Amin ARMR, Wang D, Zhang H, Peng S, Shin HJCS, et al. (2010). Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin potential role of p53. J Biol Chem 285: 34557-65.
56. Betuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, et al. (2006). Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234-1240.
57. 198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A 109: 12426-31.
58. Castelletti F, Donadelli R, Banterla F, Hildebrandt F, Zipfel PF, et al. (2008). Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 105: 2538-43.
59. Leask A, Abraham DJ (2004). TGF-b signaling and the fibrotic response. FASEB J 18: 816-27.